Monopar Therapeutics (MNPR) Selling, General & Administrative (2017 - 2026)

Monopar Therapeutics (MNPR) Selling, General & Administrative (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 582.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 662.10 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1.13 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 110.21 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 593.21 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 2,715.95
7 Royalty Pharma 33.72 Bn 35.84 Bn - 161.89 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 347.92 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 247.47 Mn
10 Monopar Therapeutics 965.64 Mn 912.88 Mn - 1.88 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 1.88 Mn
Sep 30, 2025 1.50 Mn
Jun 30, 2025 1.50 Mn
Mar 31, 2025 1.58 Mn
Sep 30, 2024 590,624.00
Jun 30, 2024 657,806.00
Mar 31, 2024 757,281.00
Sep 30, 2023 749,474.00
Jun 30, 2023 733,496.00
Mar 31, 2023 871,675.00
Dec 31, 2022 806,030.00
Sep 30, 2022 675,115.00
Jun 30, 2022 684,877.00
Mar 31, 2022 779,254.00
Dec 31, 2021 698,441.00
Sep 30, 2021 631,698.00
Jun 30, 2021 615,965.00
Mar 31, 2021 687,936.00
Dec 31, 2020 628,377.00
Sep 30, 2020 392,063.00